Excelsus Structural Solutions SPRL was created in March 2012 as a spin-off company of the Paul Scherrer Institute (PSI), the largest federal research center for natural and engineering sciences within Switzerland. Its main offices are located in Brussels (Belgium) whereas it operates primarily at the PSI synchrotron facility in Switzerland.


In February 2014, Excelsus Structural Solutions (Swiss) AG based in Switzerland was founded to ensure the prompt access of the ESS team to the synchrotron laboratories and facilitate the interaction with the local scientists. Since April 2016, Excelsus Structural Solutions (Swiss) AG is part of Switzerland Innovation PARK INNOVAARE. More on ESS (Swiss) AG transition to Switzerland Innovation PARK INNOVAARE. Interview to founder Dr Fabia Gozzo.


Excelsus Structural Solutions offers easy and affordable access to unique Synchrotron-based characterization tools developed at the Paul Scherrer Institute, to enhance the selection, development and manufacturing of high-quality (bio)pharmaceutical products.


Excelsus Structural Solutions Team of experienced synchrotron scientists with many years of experience in ab-initio structural solution, qualitative and quantitative phase analysis applied to pharmaceuticals will assist you in the definition of the best strategy to takle your specific problem, the conception of the appropriate experimental plan and the development and realization of it. Excelsus' Team will take care of sample preparation, definition of the most appropriate experimental conditions and protocol, data collection, reprocessing, analysis and interpretation and deliver to you a detailed experimental report that suits your specific needs, as defined by you.


Excelsus Structural Solutions team will make available to you the latest advanced Synchrotron X-Ray Powder Diffraction experimental data collection data analysis strategies that have made it possible the detection and quantification of traces of minority phases as low as 0.01% wt in organic pharmaceutical compounds. Level of Detection (LoD) and Level of Quantification (LoQ) as low as 0.01% wt have been recently demonstrated in organic pharmaceutical compounds when using unconventional beamline optics set up developed by Excelsus Team. MORE on 0.01% wt LoD.


The experience of highly qualified professionals in our team providing engineering and scientific services to the industry, while handling proprietary information with high confidentiality standards, is significantly greater than the years that we have been in business.


A network of scientists worldwide allows us to be uniquely positioned to broaden our services with the high standards of Excelsus.



KEYWORDS: Synchrotron X-Ray Powder Diffraction, Pharmaceuticals, Quantitative Phase Analysis, Qualitative Phase Anlaysis, Low Level of Detection, Low Level of Quantification

Excelsus Structural Solutions AG is now visible on
23rd February 2018
Excelsus Structural Solutions AG is now visible on which provides a searchable overview on ETH Domain spin-offs.
Read more ›
Our new article is available on the PharmTech website
5th February 2018
Our new article 'The Power of Synchrotron X-Ray Powder Diffraction for the Characterization of Pharmaceuticals' is now available on the PharmTech website !
Read more ›
ESS is pleased to announce the collaboration with Improved Pharma LLC
5th February 2018
Excelsus Structural Solutions is proud to announce a collaboration with Improved Pharma LLC (co-founded by Stephen Byrn, Professor at Purdue University, USA) to provide services re ...
Read more ›
Women in R&D and Innovation @ the IBM Research THINKLab - Zurich
26th November 2017
On November 27th at the prestigious IBM Labs in Ruschlikon near Zurich, an interesting event is organized by Dr Karin Vey (Executive Innovation Consultant at IBM Research) on the ...
Read more ›
Our Customers
Privacy    Cookie Policy
realizzazione siti web